Case Study

Completing Recruitment In 3 Countries In A Phase 2b Study Despite Hurdles Caused By The Pandemic

Source: OCT Clinical
GettyImages-1372189785 waiting room

Of the world's population, 7.5% report having lower back pain, and eight out of 10 people in the U.S. will experience it in their lifetime. With no long-term treatment options other than surgery, most of these patients continue to suffer.

A leading Eastern European CRO OCT Clinical partnered with a Sweden-based pharmaceutical company called Stayble Therapeutics to run a Phase 2b study in three countries in Europe. This is a multicenter, randomized study, the primary goal of which is to evaluate the efficacy of the study medicine vs. placebo. The study is double-blinded, which means that neither the patient nor the treating physician knows whether the patient is receiving a high or low dose of STA363—the medicine under study—or a placebo. All trial participants are followed up for 12 months.

Download the full text to learn more about this study’s outcomes.

access the Case Study!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader